Prothrombin fragment 1.2 was more frequently elevated in patients with cardiomyopathy compared to those with cardiac assist devices (61.1% vs 15.7%; P=0.0002).
Observational (n=81)
How do coagulation and hemostasis biomarker profiles differ among patients with chronic cardiovascular diseases such as cardiomyopathy and those with heart assist devices?
In patients with chronic cardiovascular disease, elevated PF1.2 suggests thrombin generation in cardiomyopathy, whereas isolated D-dimer elevation in patients with heart assist devices likely reflects the device presence rather than systemic hemostatic activation.
Absolute Event Rate: 61.1% vs 15.7%
p-value: p=0.0002
Measurement of a single marker of coagulation may not provide a complete picture of hemostasis activation and fibrinolysis in patients with chronic cardiovascular diseases. We assessed retrospective orders of a panel which included prothrombin fragment 1.2 (PF1.2), thrombin: antithrombin complexes, fibrin monomers, and D-dimers in patients with heart assist devices, cardiomyopathies, atrial fibrillation and intracardiac thrombosis (based on ordering ICD-10 codes). During 1 year there were 117 panels from 81 patients. Fifty-six (69%) patients had heart assist devices, cardiomyopathy was present in 17 patients (21%) and 29 patients (36%) had more than 1 condition. PF1.2 was most frequently elevated in patients with cardiomyopathy (61.1%) compared to those with cardiac assist devices (15.7%; P = 0.0002). D-dimer elevation was more frequent in patients with cardiac assist devices (98.8%) compared to those patients with cardiomyopathy (83.3%; P = 0.014). Patients with cardiomyopathy show increases of PF1.2 suggesting thrombin generation. In contrast, elevations of D-dimers without increase in other coagulation markers in patients with cardiac assist devices likely reflect the presence of the intravascular device and not necessarily evidence of hemostatic activation.
Miller et al. (Fri,) conducted a observational in Chronic cardiovascular disease (n=81). Coagulation and hemostasis biomarker panel vs. Cardiac assist devices was evaluated on Elevation of prothrombin fragment 1.2 (PF1.2) (p=0.0002). Prothrombin fragment 1.2 was more frequently elevated in patients with cardiomyopathy compared to those with cardiac assist devices (61.1% vs 15.7%; P=0.0002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: